Inadequate reporting of adjudicators in open-label trials of anticancer drugs between 2017 and 2021: a methodological review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inadequate reporting of adjudicators in open-label trials of anticancer drugs between 2017 and 2021: a methodological review

Published:2022-10 Issue: Volume:150 Page:80-89
ISSN:0895-4356
Container-title:Journal of Clinical Epidemiology
language:en
Short-container-title:Journal of Clinical Epidemiology

Author:

Funada Satoshi^ORCID,Luo Yan,Kataoka Yuki,Yoshioka Takashi,Fujita Yusuke,Yoshida Shinya,Katsura Morihiro,Tada Masafumi,Nishioka Norihiro,Nakamura Yoshiaki,Furukawa Toshi A.

Publisher

Elsevier BV

Subject

Epidemiology

Reference16 articles.

1. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov;Hirsch;JAMA Intern Med,2013

2. Clinical trial evidence supporting US Food and drug administration approval of novel cancer therapies between 2000 and 2016;Ladanie;JAMA Netw Open,2020

3. FDA acceptance of surrogate end points for cancer drug approval: 1992-2019;Chen;JAMA Intern Med,2020

4. RoB 2: a revised tool for assessing risk of bias in randomised trials;Sterne;BMJ,2019

5. Protocol for detection bias in open-label trials of cancer drugs: a meta-epidemiologicalstudy;Funada,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study;BMJ Evidence-Based Medicine;2023-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP